

PRESS RELEASE

New SynTiso line concept from Syntegon revolutionizes liquid pharmaceutical filling

- Joint development with partners from the pharmaceutical industry
- The highest output in the market: up to 600 containers per minute
- Significantly reduced contamination risk thanks to full automation and contactless, suspended transport

Waiblingen (Germany), May 28, 2025. At Pharmatag 2025 in Crailsheim, [Syntegon](#) presented a new line concept for liquid pharmaceuticals. SynTiso was developed in collaboration with two partners from the pharmaceutical industry and addresses the current challenges of pharmaceutical manufacturers regarding high performance and availability as well as maximum product yield and minimal operator intervention. “As a strategic partner to the pharmaceutical industry, we will revolutionize filling operations together with our customers,” says Stephan März, Executive VP Pharma Liquid at Syntegon.

Fully automated and Annex 1-compliant

Thanks to the gloveless isolator, pharmaceutical manufacturers can automate their processes and minimize human intervention. “But we go one step further with SynTiso: the robots are generally located as far away from the process as possible and are only used for aseptic setup and as needed,” explains product manager Markus Heinz. This provides customers with an Annex 1-compliant solution including the First Air principle, which allows air to circulate freely. “The position of the robots also minimizes particles in the aseptic area, which in turn significantly reduces the risk of contamination,” says Heinz. Real-time monitoring of germs and particles also eliminates the need to exchange settle plates.

Innovative, contactless transport

The new contactless, suspended transport generates no particles and facilitates cleaning and maintenance, even with highly potent pharmaceuticals such as oncological drugs, among other things thanks to a smaller number of components within the isolator. The system ensures faster aseptic transport and up to 50 percent shorter batch changeovers in a smaller space. With 100 percent in-process control (IPC), SynTiso can process up to 600 syringes, vials, or cartridges per minute — a speed never before seen on the market. “This is an important factor, for example in vaccine production,” Heinz explains. “Of course, SynTiso is also suitable for filling the increasingly popular [ready-to-use \(RTU\) containers](#).”

Working together to advance the vision

“As a strategic partner to our customers, we once again focused on joint development — and have integrated pharmaceutical processes into the system design of SynTiso right from the start,” Stephan März emphasizes. “The result is impressive: this line concept brings us a big step forward toward our vision of a virtually empty isolator, which will deliver significantly greater flexibility and faster availability.”

###

Images



SynTiso was developed in collaboration with two partners from the industry and addresses the current challenges of pharmaceutical manufacturers.



With 100 percent in-process control (IPC), SynTiso can process up to 600 syringes, vials, or cartridges per minute — a speed never before seen on the market.

Contact

Daniela Goetz
Spokesperson Product Communications Pharma Liquid
+49 7951 402-620
daniela.goetz@syntegon.com

About Syntegon

Syntegon is a leading global technology company and strategic partner to the pharmaceutical, biotech and food industries. With a strategic focus on the growing pharmaceutical and biotech sectors, Syntegon plays a vital role in global healthcare, providing in-depth process expertise and mission-critical technologies for the safe, efficient, and compliant production of essential medicines. In the food sector, Syntegon is recognized for high-speed, high-precision packaging solutions, drawing on unique engineering excellence to help manufacturers improve performance and product quality. Its global service business supports about 76,000 installed systems with a comprehensive lifecycle offering, ensuring uptime, efficiency, and long-term value.

In fiscal year 2024, Syntegon generated 1.6 billion euros in sales. Headquartered in the Stuttgart region in Germany, the company employs 6,900 people at 47 locations in more than 20 countries. With over 160 years of industry expertise, Syntegon delivers solutions that make a real difference, helping people live better, stay healthier, and trust the products they rely on every day.

www.syntegon.com